Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Nabil V. Sayour"'
Autor:
Brachyahu M. Kestecher, Krisztina Németh, Sayam Ghosal, Nabil V. Sayour, Tamás G. Gergely, Bernadett R. Bodnár, András I. Försönits, Barbara W. Sódar, Johannes Oesterreicher, Wolfgang Holnthoner, Zoltán V. Varga, Zoltán Giricz, Péter Ferdinandy, Edit I. Buzás, Xabier Osteikoetxea
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-14 (2024)
Abstract Aims The association and co-isolation of low-density lipoproteins (LDL) and extracellular vesicles (EVs) have been shown in blood plasma. Here we explore this relationship to better understand the role of EVs in atherogenesis. Methods and re
Externí odkaz:
https://doaj.org/article/96be4664a30a4f128e0112c34002fecd
Autor:
Csenger Kovácsházi, Szabolcs Hambalkó, Nabil V. Sayour, Tamás G. Gergely, Gábor B. Brenner, Csilla Pelyhe, Dóra Kapui, Bennet Y. Weber, Alexander L. Hültenschmidt, Éva Pállinger, Edit I. Buzás, Ádám Zolcsák, Bálint Kiss, Tamás Bozó, Csilla Csányi, Nikolett Kósa, Miklós Kellermayer, Róbert Farkas, Gellért B. Karvaly, Kieran Wynne, David Matallanas, Péter Ferdinandy, Zoltán Giricz
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Hypercholesterolemia (HC) induces, propagates and exacerbates cardiovascular diseases via various mechanisms that are yet not properly understood. Extracellular vesicles (EVs) are involved in the pathomechanism of these diseases. To understa
Externí odkaz:
https://doaj.org/article/af891ef4f6eb4aa6a97926bd769c49dc
Autor:
Dániel Kucsera, Viktória E. Tóth, Nabil V. Sayour, Tamás Kovács, Tamás G. Gergely, Mihály Ruppert, Tamás Radovits, Alexandra Fábián, Attila Kovács, Béla Merkely, Péter Ferdinandy, Zoltán V. Varga
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-14 (2023)
Abstract Interleukin-1β (IL-1β) is a key mediator of non-alcoholic steatohepatitis (NASH), a chronic liver disease, and of systemic inflammation-driven aging. IL-1β contributes to cardio-metabolic decline, and may promote hepatic oncogenic transfo
Externí odkaz:
https://doaj.org/article/4c0e61863a41496687dce854be03e766
Autor:
Bennet Y. Weber, Gábor B. Brenner, Bernadett Kiss, Tamás G. Gergely, Nabil V. Sayour, Huimin Tian, András Makkos, Anikó Görbe, Péter Ferdinandy, Zoltán Giricz
Publikováno v:
Pharmaceuticals, Vol 15, Iss 9, p 1055 (2022)
Clinical observations are highly inconsistent with the use of the antidiabetic rosiglitazone regarding its associated increased risk of myocardial infarction. This may be due to its hidden cardiotoxic properties that have only become evident during p
Externí odkaz:
https://doaj.org/article/be592a902bfc4549be3705bd481e22c9
Autor:
Gábor B. Brenner, András Makkos, Csilla Terézia Nagy, Zsófia Onódi, Nabil V. Sayour, Tamás G. Gergely, Bernadett Kiss, Anikó Görbe, Éva Sághy, Zoltán S. Zádori, Bernadette Lázár, Tamás Baranyai, Richárd S. Varga, Zoltán Husti, András Varró, László Tóthfalusi, Rainer Schulz, István Baczkó, Zoltán Giricz, Péter Ferdinandy
Publikováno v:
Cells, Vol 9, Iss 3, p 551 (2020)
Cardiac adverse effects are among the leading causes of the discontinuation of clinical trials and the withdrawal of drugs from the market. The novel concept of ‘hidden cardiotoxicity’ is defined as cardiotoxicity of a drug that manifests in the
Externí odkaz:
https://doaj.org/article/e64b79f188254c80abf4399ea382fcad
Autor:
Nabil V Sayour, Gábor B Brenner, András Makkos, Bernadett Kiss, Csenger Kovácsházi, Tamás G Gergely, Sverre Groever Aukrust, Huimin Tian, Viktória Zenkl, Kamilla Gömöri, Tamara Szabados, Péter Bencsik, Andre Heinen, Rainer Schulz, Gary F Baxter, Coert J Zuurbier, Zoltán Vokó, Péter Ferdinandy, Zoltán Giricz
Publikováno v:
Caridovascular Research
Aims Remote ischaemic preconditioning (RIPC) is a robust cardioprotective intervention in preclinical studies. To establish a working and efficacious RIPC protocol in our laboratories, we performed randomized, blinded in vivo studies in three study c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e55da7594a19f5748a9ee0f34af99645
https://doi.org/10.1093/cvr/cvad024
https://doi.org/10.1093/cvr/cvad024
Autor:
Tamás G, Gergely, Dániel, Kucsera, Viktória E, Tóth, Tamás, Kovács, Nabil V, Sayour, Zsófia D, Drobni, Mihály, Ruppert, Balázs, Petrovich, Bence, Ágg, Zsófia, Onódi, Nóra, Fekete, Éva, Pállinger, Edit I, Buzás, Laura I, Yousif, Wouter C, Meijers, Tamás, Radovits, Béla, Merkely, Péter, Ferdinandy, Zoltán V, Varga
Publikováno v:
British journal of pharmacology.
Immune checkpoint inhibitors (ICI), such as anti-PD-1 monoclonal antibodies, have revolutionized cancer therapy by enhancing cytotoxic effects of T cells against tumours. However, enhanced T cell activity may cause myocarditis and cardiotoxicity. Nev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0eae282297da90965df23b55bb392bc7
https://pubmed.ncbi.nlm.nih.gov/36356191
https://pubmed.ncbi.nlm.nih.gov/36356191
Autor:
Tamás G. Gergely, Gábor B. Brenner, Regina N. Nagy, Nabil V. Sayour, András Makkos, Csenger Kovácsházi, Huimin Tian, Rainer Schulz, Zoltán Giricz, Anikó Görbe, Péter Ferdinandy
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 2; Pages: 1585
Lipid-lowering drugs have been shown to have cardioprotective effects but may have hidden cardiotoxic properties. Therefore, here we aimed to investigate if chronic treatment with the novel lipid-lowering drug bempedoic acid (BA) exerts hidden cardio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9895a57b26f7f6c53de6af7985474185
https://doi.org/10.3390/ijms24021585
https://doi.org/10.3390/ijms24021585
Autor:
Gábor B, Brenner, Zoltán, Giricz, Rita, Garamvölgyi, András, Makkos, Zsófia, Onódi, Nabil V, Sayour, Tamás G, Gergely, Tamás, Baranyai, Örs, Petneházy, Dénes, Kőrösi, Gergő P, Szabó, Hajnalka, Vago, Zsófia, Dohy, Csilla, Czimbalmos, Béla, Merkely, Swetlana, Boldin-Adamsky, Elena, Feinstein, Iván G, Horváth, Péter, Ferdinandy
Publikováno v:
Journal of visualized experiments : JoVE. (170)
The development of heart failure is the most powerful predictor of long-term mortality in patients surviving acute myocardial infarction (MI). There is an unmet clinical need for prevention and therapy of post-myocardial infarction heart failure (pos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e2e59e6cacfd16831bf4b6a87caaa67c
https://pubmed.ncbi.nlm.nih.gov/33938885
https://pubmed.ncbi.nlm.nih.gov/33938885
Autor:
Péter Ferdinandy, Tamás G Gergely, Dénes Kőrösi, Elena Feinstein, Iván Horváth, Örs Petneházy, Rita Garamvölgyi, Csilla Czimbalmos, Zoltán Giricz, Gábor B. Brenner, Swetlana Boldin-Adamsky, Nabil V Sayour, Tamás Baranyai, G Szabo, Zsófia Dohy, Béla Merkely, András Makkos, Hajnalka Vágó, Zsófia Onódi
Publikováno v:
Journal of Visualized Experiments.
The development of heart failure is the most powerful predictor of long-term mortality in patients surviving acute myocardial infarction (MI). There is an unmet clinical need for prevention and therapy of post-myocardial infarction heart failure (pos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07b036db689c1d4a08801f8abf8ce7c5
https://doi.org/10.3791/61901-v
https://doi.org/10.3791/61901-v